作者：伯戏来源：原创时间：2026-08-26 阅读：462183 次

legal high

PM to visit Una and Chamba in Himachal on Thursday_我的网站

一 | K图 688356_0 K图 688185_0 　　两只热门概念股，双双发布股价异动公告。 New Delhi, Oct 12 (UNI) Prime Minister Narendra Modi will visit Una and Chamba in Himachal Pradesh on Thursday and launch various developmental initiatives in the state.

In Una, Prime Minister will flag off Vande Bharat Express from Una Himachal railway station.

Running from Amb Andaura to New Delhi, it will be the fourth Vande Bharat train to be introduced in the country and is an advanced version compared to the earlier ones, being much lighter and capable of reaching higher speed in shorter duration, the PMO said.

The train accelerates to 100 Km/h in just 52 seconds.

The introduction of the train will help boost tourism in the region and provide a comfortable and faster mode of travel.

Thereafter, in a public function, the Prime Minister will dedicate IIIT Una to the nation and lay the foundation stone of Bulk Drug Park in Una.

The foundation stone of the IIT was laid by the Prime Minister in 2017. Currently more than 530 students are pursuing study in this Institute.

The Prime Minister will lay the foundation stone of Bulk Drug Park at Haroli in Una district, which will be built at a cost of over Rs 1900 crore.

The Park will help reduce dependence on API imports, the PMO said.

It is expected to attract investment of around Rs 10,000 crores and provide employment to more than 20,000 people. It will also give a fillip to economic activities in the region.

The Prime Minister will lay the foundation stone of two hydropower projects - the 48 MW Chanju-III Hydro-electric Project and the 30 MW Deothal Chanju Hydro-electric Project.

Both these projects will generate over 270 million units of electricity annually and Himachal Pradesh is expected to get annual revenue of around Rs. 110 crore from these projects, the PMO said.

The Prime Minister will also launch Pradhan Mantri Gram Sadka Yojana (PMGSY)-III in Himachal Pradesh for upgradation of around 3125 kms of roads in the State.

More than Rs 420 crore has been sanctioned by the Central Government under this phase for the upgradation of 440 kms of roads in 15 border and far flung Blocks of the State.

UNI ASU GNK。
　　受海外医药巨头默沙东与Moderna（莫德纳）合作研发的个性化mRNA抗癌疫苗intismeran的III期临床试验研究成功的消息影响，键凯科技（688356）于8月20日和8月21日连续“20cm”涨停。　　8月21日晚间，键凯科技披露异动公告称，经公司自查，公司目前生产经营活动一切正常。市场环境、行业政策没有发生重大调整，生产成本和销售等情况没有出现大幅波动，内部生产经营秩序正常。公司控股股东、实控人也不存在涉及公司应披露而未披露的重大信息。　　针对市场传闻情况，公告称，经公司自查，公司未直接向Moderna提供LNP核心原料。mRNA肿瘤疫苗的商业化对公司业务的影响主要体现在两个方面。

二 | 　　第一是材料销售业务方面，2025年，公司LNP类产品收入约751.21万元，占公司当年营业收入的比例较小，约为2.36%。公司预计短期内LNP相关的产品销售业务不会对公司材料销售收入情况产生重大影响。

三 | 　　第二是研发管线方面，公司与康希诺（688185）合作的针对胶质母细胞瘤的mRNA疫苗项目，以及公司自研的mRNA肿瘤疫苗项目，目前均处于临床前研究阶段，存在较大不确定性。

四 | 公司与康希诺共同开发的三组分LNP递送系统ISL-3C-LNP目前已向第三方授权，由于授权方项目尚处在临床前早期研究阶段，也存在较大不确定性。　　证券时报记者注意到，键凯科技异动公告中所提到的康希诺，在8月21日晚间同样发布了异动公告。

五 | 二级市场上，康希诺同样于8月20日和8月21日连续两个交易日“20cm”涨停。　　康希诺公告称，公司关注到近期市场上关于mRNA技术的发展。mRNA平台是公司布局的技术平台之一，公司正在进行mRNA预防用疫苗及治疗性生物制品的开发，以及相关递送系统的开发。治疗领域方面，公司正在推进mRNA疫苗用于治疗胶质母细胞瘤、横纹肌肉瘤及宫颈癌等适应症的研发工作，以及InVivoCAR相关疗法的开发，目前均处于早期阶段。　　除此之外，康希诺强调，公司目前生产经营活动正常，内部经营秩序正常。公司及公司控股股东、实控人不存在应披露而未披露的重大事项。（文章来源：证券时报）。